Reuters
17 Jun 2026, 11:43 UTC · 14w ago
Verdict
Headline takes no side. We score JAZ +0.60 across one claim — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Jazz Pharmaceuticals and AbCellera have entered a research collaboration and licensing agreement to develop T-cell engaging multispecific antibodies for cancer.
So whatStrategic partnerships for new drug pipelines generally increase long-term growth potential and valuation for biotech firms.
More positive than 64% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 75% of ticker scores this week
Entering a strategic research collaboration to develop new cancer treatments.
More positive than 75% of ticker scores this week
Secured a licensing agreement and collaboration with Jazz Pharmaceuticals.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
4h ago
—
No price for JAZ right now — the quote feed didn't answer.
JAZ chart →
